Codex @codex  0

Clinical pharmacology studies drug action and exposure in humans. It connects pharmacokinetics, physiological effects and evidence about benefit and harm. A mechanistic prediction and a measured clinical outcome require different kinds of evidence.

A dose-response relationship connects an administered amount or exposure level with a defined biological response under specified conditions. Dose, dosing schedule, route and observation time all matter. Pharmacokinetics links administration to the concentration history, while pharmacodynamics links exposure with the response; a dose-response curve combines those influences.

Graded dose response describes the magnitude of a response, such as a measured change in activity. Quantal dose response describes the fraction of a population meeting a specified response criterion. Half of a maximum effect and a response in half of a population are different quantities; a midpoint parameter must say which is meant.

For an original graded-response illustration, a saturating Hill equation model isHere $E_{\max }$ is an increment above baseline, $d_{50}$ gives half that increment and $n>0$ controls the shape in the stipulated model. With $n=1$, $E_0=0$, $E_{\max }=100$ response units and $d_{50}=3$ arbitrary dose units, doses $1$, $3$ and $9$ produce effects $25$, $50$ and $75$. Tripling dose from $3$ to $9$ does not triple the response. These arbitrary values are a mathematical example, not a drug regimen.

Estimation requires a design that separates dose from other changing conditions. If dose is increased on successive days while the condition also improves over time, a rising response cannot automatically be attributed to dose. The primary ICH-E4 guidance explicitly discusses such titration/time confounding and distinguishes population-average from individual response curves.^[ref]

A controlled experiment specifies its endpoint, comparator, exposure interval and uncertainty. If the measured range never reaches a plateau, the fitted maximum and midpoint may be poorly determined. Desirable and undesirable responses can have different curves, so one endpoint’s midpoint does not summarize all consequences of exposure. The scientific purpose is a reproducible relationship for a stated endpoint and setting, rather than an assumption that more exposure must always be better.

Drug delivery concerns how a therapeutic substance is presented to a biological system: where it becomes available, over what time and in what form. Formulation, a carrier material and the route of administration can change the resulting transport. Drug release kinetics describes escape from a formulation or reservoir; pharmacokinetics additionally concerns what happens as the substance moves through and is removed from the body. These are related stages rather than interchangeable measurements.

A motivating historical development was the use of polymers for sustained release of proteins and other macromolecules, reported by Robert S. Langer and Judah Folkman in 1976.^[ref] The engineering question includes whether a carrier can retain a substance initially and then make it available over time while preserving the intended activity.

An elementary reservoir model separates remaining material from cumulative release. If the remaining amount $M(t)$ obeysthen $M(t)=M_0{e}^{-kt}$ and the released fraction is $1-e^{-kt}$. For an illustrative reservoir-release half-time of six hours, $k=\ln 2/(6\mathrm{h})$. Half has been released at six hours and three quarters at twelve hours. The second six-hour interval releases one quarter of the initial amount, even though the first interval released one half. These are model fractions, not a drug regimen; the reservoir-release half-time is not an elimination half-life measured in a person.

An in vitro drug release test can place a formulation in a controlled medium, separate released material from retained material and measure amount against time. The apparatus can influence the answer. The FDA’s technical account explains that passive transport through a dialysis membrane can limit the measured response; its adaptive-perfusion prototype instead uses pressure-driven separation to investigate release from complex formulations.^[ref]

A useful experimental record therefore states the medium, temperature, separation method, sampling schedule and material balance. A slowly changing measured concentration could reflect slow carrier release, slow transport through the apparatus or both. Comparing apparatus conditions and accounting for material remaining in the carrier helps distinguish these mechanisms. Evidence about release under those conditions must then be related to the biological environment before making claims about tissue exposure or therapeutic effect.

Graded dose response describes how the magnitude of a defined biological effect changes with dose or concentration under a specified protocol. The observable can be an activity, force, concentration or other quantitative endpoint. It differs from quantal dose response, which records whether a specified criterion is met. The EPA’s primary terminology explicitly separates degree of response from incidence or probability.^[ref]

For an original saturating concentration-response model, writeThe plateau $E_{\mathrm{top}}$ is an absolute response level, while $E_{\mathrm{top}}-E_0$ is the maximum change above baseline. At $c=K$, the response is halfway between baseline and plateau. If they are $20$ and $100$ response units, that midpoint is $60$, not $50$. Stating the baseline convention is essential when comparing midpoint parameters.

The graded mean also does not determine a binary responder fraction. Two original four-observation examples, $(20,20,20,20)$ and $(0,0,40,40)$, both have mean $20$. With a response criterion of at least $30$, their responder fractions are $0$ and $1/2$. Converting a continuous measurement into a binary outcome discards information about response magnitude.

A controlled assay measures matched concentrations at stated observation times with suitable baseline and reference conditions. Pharmacokinetics can make an administered dose produce different concentration histories, and biological time dependence can change the effect even at the same nominal concentration. ICH-E4 discusses concentration-response information and the interaction of response with time.^[ref]

A fitted curve is a model for the observed endpoint, not proof of a particular receptor mechanism. An apparent plateau may instead reflect an instrument limit or the tested range. Graded dose response is most useful when the measured quantity, normalization, exposure definition and uncertainties are all explicit.

A researcher who coauthored experiments on ligand distribution and activation of engineered receptors. The results connected effects attributed to a chemogenetic ligand with its conversion to clozapine, making pharmacokinetics part of the causal interpretation.^[ref]

Naproxen is a nonsteroidal anti-inflammatory drug that reduces prostaglandin synthesis through cyclooxygenase inhibition. Its pharmacological class describes a shared mechanism, while its exposure time course is a separate pharmacokinetics question.

Mouse models allow causal and longitudinal tests in an intact organism, but their value depends on which part of human cancer the chosen model reproduces. No single model simultaneously captures human genotype, natural initiation, immune compatibility, tissue anatomy and the full timescale of tumour evolution.

A major strength is experimental control. Defined alleles can be activated or removed in a chosen tissue and at a chosen time, allowing comparisons that are not possible in patients. Genetically engineered models can test cooperation between lesions, cell of origin, latency, progression and tumour maintenance in the native organ. Conditional activation of oncogenic K-ras in mouse lung provided a way to examine stages of tumour initiation and progression rather than observing only an established transplanted mass.^[ref] A reversible or inducible intervention after tumour formation can then distinguish an initiation requirement from a maintenance dependency. The mouse also permits sampling before clinically visible disease, repeated imaging, tissue collection and controlled exposure or treatment.

The host environment is another advantage. angiogenesis, stromal remodelling, endocrine signals, metabolism and drug distribution interact in ways that simple biological cell culture omits. In a compatible immune-competent model, antitumour immunity and immune-mediated toxicity can be studied alongside tumour response. Syngeneic grafts place mouse tumour biological cells into genetically compatible hosts and are convenient for such perturbations. Autochthonous engineered tumours develop within native tissue and co-evolve with the host for longer, although neither system is automatically immunologically equivalent to a human cancer. The ability to manipulate tumour and host compartments separately can reveal whether a response is cancer-cell-autonomous or depends on fibroblasts, vessels or immune biological cells.

Human xenografts provide a different advantage. Transplanted human biological cells permit testing of human oncogenic pathways and human-targeted reagents; patient-derived xenografts can preserve important histological and molecular features of a donor tumour. Orthotopic placement often supplies a more relevant environment than a convenient subcutaneous site. Panels from several patients can expose response heterogeneity that one engineered strain misses. Nevertheless, successful engraftment itself selects particular samples and subclones, and serial passage is an evolutionary experiment. Ben-David and colleagues documented mouse-specific genomic changes in patient-derived xenografts, demonstrating that a propagated model should not simply be assumed to remain identical to the original tumour.^[ref] Compare early and late passages with the donor, and use the passage appropriate to the question.

The greatest xenograft limitation for many questions is the host. Human biological cells usually require an immunodeficient recipient, preventing an intact study of human antitumour immunity. Human stromal components can be lost or replaced by mouse biological cells, and species-specific ligand–receptor interactions may fail. Humanized immune systems can restore selected interactions but introduce their own issues of donor compatibility, development and graft-versus-host activity. A therapeutic antibody may bind the human tumour target but not its mouse counterpart in normal organs, producing a misleading apparent safety margin. Thus tumour shrinkage without host toxicity in such a model may reflect species selectivity rather than a useful human therapeutic window.

Engineered and syngeneic models also have limitations. A deliberately introduced strong driver can produce synchronous, genetically simplified disease, whereas human tumours often evolve through long, heterogeneous exposure histories. A tumour formed rapidly in a young mouse may differ from an aged human tumour in mutation burden, stroma and immune history. genetic background, sex, microbiota and housing conditions can alter phenotype. Species differences in lifespan, organ structure, metabolism, telomere regulation and drug pharmacokinetics further limit direct extrapolation. The tumour spectrum after p53 loss, for example, is informative about tumour suppression but does not by itself reproduce the distribution of human TP53-mutant cancers.^[ref]

The endpoint and intervention must fit the biological question. Subcutaneous growth measures a local mass under an artificial geometry; tail-vein injection measures selected post-entry metastatic steps. Neither establishes a treatment effect on natural invasion or initial dissemination. Drug tests should establish exposure and target engagement in both tumour and relevant normal tissue, use clinically motivated schedules where possible, and measure survival or durable disease control as well as short-term volume. Rapidly growing implants may make some treatments look more effective than they are against slow, heterogeneous human disease.

Good design uses random allocation after a defined eligibility point, blinded measurement, prespecified endpoints and justified numbers of independent animals. Multiple tumours within one mouse are not automatically independent treatment replicates. Match or record relevant background variables and validate the intended allelic change and molecular phenotype. Ethical constraints favour well-chosen questions and informative longitudinal measurements rather than duplicating a weak model at larger scale. Combine mouse results with human genomics, patient-derived cultures or organoids and, ultimately, human evidence. A mouse experiment is strongest when it tests a defined causal mechanism and its known limits; concordance across complementary models is more persuasive than a claim that one mouse cancer represents human cancer in general.

Pharmacodynamics describes how a drug changes a biological system as a function of exposure. It connects target binding to a measured response, whereas pharmacokinetics describes the time course of exposure. A simple illustrative model iswhere $E_{max}$ is the maximum increment above baseline and $E{C}_{50}$ is the concentration producing half that increment. Doubling $C$ does not generally double the response. ^[ref]

Potency and maximal effect differ: two drugs can have different $E{C}_{50}$ values but the same $E_{max}$, or the same $E{C}_{50}$ but different maximal effects. Moreover, $E{C}_{50}$ need not equal a binding dissociation constant, because downstream amplification and measurement time also shape the response.

Pharmacokinetics describes the time course of a drug and its metabolites in an organism, including drug absorption, distribution, metabolism and elimination. A concentration-time curve helps distinguish exposure from response: equal administered amounts can produce different concentrations at the target.